Young Adult Hub
Visit Hub
Weight loss is one of the most effective ways of reducing joint pain, so are weight-loss medications (such as GLP-1 medicines: semaglutide, tirzepatide and liraglutide) a good idea?
Written by Dr Wendy Holden, Medical Advisor & Honorary Consultant Rheumatologist and Martin Lau, Services Manager & Dietitian | Published 14 July 2026
Glucagon-like peptide-1 receptor agonists (GLP-1) are medicines that mimic the effects of a natural hormone called Glucagon-like Peptide-1 which is released by the gut and causes feelings of fullness and reduced appetite.
These medicines were originally designed for people with type-2 diabetes to help control blood glucose levels, but as they can cause reduced appetite, they can also lead to reduced eating and weight loss.
These medicines have been widely publicised as wonder drugs for treating obesity because unlike conventional diets which are hard to maintain, GLP-1 agonists can lead to relatively easy weight loss by reducing food craving and encouraging healthy eating.
Examples of GLP-1 agonists include semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro) and liraglutide (Saxenda). Tirzepatide has a GLP-1 action and also mimics another hormone in the body called GIP (glucose-dependent insulinotropic polypeptide), which can also reduce appetite.
Semaglutide and tirzepatide are both given by weekly injection and liraglutide as a daily injection. A once daily tablet of semaglutide has also been approved on the NHS for both type-2 diabetes and weight management and other versions are likely to follow soon.
The National Institute for Health and Care Excellence (NICE 2023) recommended NHS funding of semaglutide in combination with exercise and a calorie-controlled diet for certain overweight and obese adults, but only for a maximum of 2 yearsi.
As these medicines are not available on the NHS for many overweight people, some are increasingly turning to private weight-loss clinics and online pharmacies.
In a 2021 clinical trial, semaglutide combined with professional support and exercise lead to up to 15% loss of body weight after 68 weeks compared to 2.4% on placeboii.
Tirzepatide may be even more effective. GLP-1 medicines can also reduce the risk of cardiovascular disease including heart attack or stroke in obese people, but it is not known if this is as a result of weight loss or due to an effect of the medicine.
Exciting new evidence is now emerging that in osteoarthritis, increasing GLP-1 levels may help with pain and stiffness above and beyond the benefits of weight loss.
Researchers at the University of Nottingham, gave participants with knee osteoarthritis, either physiotherapy, a placebo medicine or a dietary supplement of inulin which is a so-called “prebiotic” fibre that can improve the gut microbiome and help it to produce anti-inflammatory molecules.
After only 6 weeks, those who took inulin, had significantly less knee pain and surprisingly increased grip strength. They also had increases in levels of GLP-1 which the authors think may be the mechanism of reduced pain and improved strengthiii. GLP-1 medicines have additional benefits in reducing the risk of cardiovascular disease such as heart attack and stroke.
In clinical trials about 78% of people given semaglutide have a side effect, the most common being nausea and vomiting and diarrhoea.
Other side effects include severe loss of appetite, reduced enjoyment of food, loss of facial fat and a gaunt face. Serious side effects include acute pancreatitis, gall bladder and kidney disease.
Real life weight loss is often less than in clinical trials and about 1 in 5 people will lose less than 5% of their body weight. As with any rapid weight loss, including fasting diets, GLP-1 medicines have been linked to muscle as well as fat loss which could affect function in older age, however research on this issue is unclear and ongoing.
GLP-1 medicines can also lead to reductions in bone mineral density, but the long-term effects of this are also uncertain.
People using GLP-1 medicines will experience a significant reduction of appetite, subsequently a decrease in calorific intake. This rapid reduction of appetite comes at a cost of macro and micro-nutrients such as protein, iron, calcium and vitamins.
Therefore, it is important to ensure that those taking these medicines ensure the make-up of their diet includes:
• Adequate fibre intake (30g per day). For example, per 100g: red beans: 11g, wholegrain bread: 8g, boiled lentils: 7g, baked beans: 5g, broccoli: 3.5g • Adequate hydration (2-4 litres of fluid per day). • Limit high calorie and low nutrient food and drinks eg milk chocolate/soft drinks. • Ensure 1.2g-1.5g protein per kg of lean mass per day which would be 120g for a 100kg person. When divided into 3 meals, each sitting should provide around 30g of protein per meal. Translating into food, a 100g of chicken breast yields around 31g of protein. Some high protein yoghurt provides 25g of protein per 200g pot. • Look to including 700mg-1g of calcium per day. Semi and skimmed milk do have slightly more calcium than their full-fat counterparts. • Getting nutrition through food is the priority but if appetite remains small, do consider a multivitamin and mineral supplement.
Learn more about diet and arthritis.
Rapid weight reduction is associated with skeletal muscle and bone loss alongside fat mass. In a clinical trial using semaglutide (Ozempic, Wegovy) once a week, of the average 13.6kg weight reduction, 8.3 kg was fat mass and 5.3 kg was lean body mass (muscle and other non-fat tissues)iv.
Skeletal muscle presents a large portion of lean mass. Loss of this will contribute to the increased risk of sarcopenia (a condition where skeletal muscle is being lost) and where loss of strength and function leads to mobility issues. Coupled with low calcium intake from reduced food intake, bone density is likely to be compromised potentially leading to osteopenia or osteoporosis.
It is well documented that a weight bearing or resistance training programme could mitigate the effects of the above. The Physical Activity Guidelinev recommends two sessions of strength training per week. Compound exercises such as squats, push ups or lifting a heavy object from the floor in a repetitive manner could help to preserve skeletal muscle mass. If you have arthritis, it is worth checking with a physiotherapist and speaking to an exercise professional before initiating any resistance training programme.
Find help and advice on exercise and arthritis.
After GLP-1 medicines are stopped, normal appetite returns and unless healthy eating habits and exercise are continued, weight gain is inevitable.
Health benefits are also lost rapidly if weight is regained. In a clinical trial, a year after stopping semaglutide, participants regained 2/3 of the weight they had lost in the trial as well as the beneficial effects on blood pressure and cholesterolvi.
In participants who continue healthy eating, however, weight loss and significant health benefits can be maintained in the longer term.
In summary, GLP-1 medicines can be extremely effective for weight loss and have health benefits, and potential benefits on osteoarthritis pain and function above and beyond the weight-loss effects.
These medicines should be used alongside healthy eating habits and exercise for the maximum benefits. Lost weight will return for most people once GLP-1 medicines are stopped if eating patterns do not change. The long-term benefits, side effects and potential for harm of these medicines are currently unknown.
Dr Wendy Holden Arthritis Action Medical Advisor and Consultant Rheumatologist
Wendy is an Honorary Consultant Rheumatologist at North Hampshire Hospitals NHS Foundation Trust, specialising in arthritis and pain management. Her main role with Arthritis Action is to help develop the charity in a way that clinicians and doctors can value and support, as part of an overall approach to managing arthritis. As well as being a hospital consultant, Wendy has additional training in pain management, acupuncture and osteopathy, and won a national award as Healthcare Champion from the National Rheumatoid Arthritis Society in 2011. She is also a Specialist Advisor to the Care Quality Commission. Wendy has a particular interest in the role of self-management alongside conventional medical care for arthritis.
Martin Lau Arthritis Action Services Manager and Dietitian
Martin was a Senior Dietitian in the NHS prior to joining Arthritis Action. He is particularly interested in eating patterns, nutrients’ interactions, weight management and persistent pain management in people living with arthritis. As well as being a Dietitian, Martin is also qualified in the field of strength and conditioning. Currently he is a member of the EULAR task force in the non-pharmacological management of Systemic Lupus Erythematosus.
i. National Institute for Health and Care Excellence (NICE). Recommendations: Semaglutide for managing overweight and obesity
ii. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989–1002.
iii. Kouraki A, Franks S, Vijay A, et al. Effect of Prebiotic Supplementation With and Without Physiotherapy on Pain and Pain Sensitivity in People with Knee Osteoarthritis. Nutrients. 2026.
iv. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
v. Department of Health and Social Care, GOV.UK. Published 7 September 2019. Physical activity guidelines: UK Chief Medical Officers’ report.
vi. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564.
Last reviewed: 14 July 2026
Healthy eating is key to getting the most from GLP-1 medicines. Explore practical nutrition advice, meal ideas and healthy eating habits to support long-term weight management.
Regular physical activity helps protect muscle and bone health while supporting weight management. Discover exercise advice to help you stay active safely and confidently.